Meda AB http://www.alacrastore.com/company-snapshot/Meda_AB-2501654 Monday, December 01, 2008 1:47:05 PM 2501654 Meda AB en AlacraStore RSS Builder 1.0 30 UK - Meda AB agreed to acquire the European operations of Valeant Pharmaceuticals International, an Aliso Viejo-based manufacturer of pharmaceuticals, for ###.### mil British pounds (#.### bil Swedish kronor/$### mil US) in cash. The transaction was subject to regulatory approval. The transaction was to exclude operations in Poland, Hungary, Slovakia, and the Czech Republic.8/6/2008 9:47:17 AM58390T91780T58390T91911XMeda ABValeant Pharmaceuticals International-European OperationsMeda ABValeant Pharmaceuticals Internationalhttp://www.alacrastore.com/storecontent/Thomson_M%26A/Meda_AB_acquires_Valeant_Pharmaceuticals_from_Valeant_Pharmaceuticals_Intl-2001608040sdc/20016080402001608040Copyright © 2008, Thomson Financial, All Rights ReservedStockholmDrugsSwedenPharmaceutical preparations2834FFForeignPublicMEDA A2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substancesDrugsUnited KingdomPharmaceutical preparations2834FFForeignSubsidiary187873003Mnfr pharm prodMnfr pharmCashCash OnlyAssets1032601001Aug 6 20080.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000170.318000.000000.00000SKR31 Mar 080.00000160.214000.000001501.380004696.42600Swedish Krona31 Dec 0731 Dec 0731 Dec 0631 Dec 0531 Dec 0431 Dec 031.986001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.0000020.0000021.0000022.0000023.0000024.0000025.0000026.0000027.0000028.0000029.0000030.0000031.0000032.0000033.00000Meda AB, located in Solna,Sweden, manufacturespharmaceutical products. Thefirm's prioritised therapyareas are cardiology,dermatology, respiratory, painand inflammation, andgastroenterology. Its productsinclude Tambocor, Cibacen,Minitran, Zanidip, Ascal,Cyklokapron, Cyklo-F, MUSE,Aldara, Betadine, Kamillosan,Novolizer, Allergodil,Allergospasmin, Zamadol,Relifex, Rantudil, Rheumin,Lederspan, Hyalart, Metanor,Reumacon, Colifoam,Proctofoam, Mic-Key, Colazid,Ursofalk, Budenofalk,Salofalk, Agiolax, Parlodel,Imovane, Thioctacid, Sargenor,Ideos and Dentan. Thecompany's operation consistsof these functions: themarketing organisation,finance, business development,scientific affairs, and Groupservices. It operates in fourgeographic areas: Central,South, Nordic, and West. Medaalso focuses on nichebusters -specialised drugs that targeta smaller patient group.Meda AB, located in Solna, Sweden, manufacturespharmaceutical products. The firm's prioritised therapyareas are cardiology, dermatology, respiratory, pain andinflammation, and gastroenterology. Its products includeTambocor, Cibacen, Minitran, Zanidip, Ascal, Cyklokapron,Cyklo-F, MUSE, Aldara, Betadine, Kamillosan, Novolizer,Allergodil, Allergospasmin, Zamadol, Relifex, Rantudil,Rheumin, Lederspan, Hyalart, Metanor, Reumacon, Colifoam,Proctofoam, Mic-Key, Colazid, Ursofalk, Budenofalk,Salofalk, Agiolax, Parlodel, Imovane, Thioctacid, Sargenor,Ideos and Dentan. The company's operation consists of thesefunctions: the marketing organisation, finance, businessdevelopment, scientific affairs, and Group services. Itoperates in four geographic areas: Central, South, Nordic,and West. Meda also focuses on nichebusters - specialiseddrugs that target a smaller patient group.Meda AB, located in Solna, Sweden, manufactures pharmaceutical products. The firm's prioritised therapy areas are cardiology, dermatology, respiratory, pain and inflammation, and gastroenterology. Its products include Tambocor, Cibacen, Minitran, Zanidip, Ascal, Cyklokapron, Cyklo-F, MUSE, Aldara, Betadine, Kamillosan, Novolizer, Allergodil, Allergospasmin, Zamadol, Relifex, Rantudil, Rheumin, Lederspan, Hyalart, Metanor, Reumacon, Colifoam, Proctofoam, Mic-Key, Colazid, Ursofalk, Budenofalk, Salofalk, Agiolax, Parlodel, Imovane, Thioctacid, Sargenor, Ideos and Dentan. The company's operation consists of these functions: the marketing organisation, finance, business development, scientific affairs, and Group services. It operates in four geographic areas: Central, South, Nordic, and West. Meda also focuses on nichebusters - specialised drugs that target a smaller patient group.1.000002.000003.000004.000005.00000The European operations ofValeant PharmaceuticalsInternational, located inWestern and Eastern Europe,manufactures pharmaceuticals.The European operations of Valeant PharmaceuticalsInternational, located in Western and Eastern Europe,manufactures pharmaceuticals.The European operations of Valeant Pharmaceuticals International, located in Western and Eastern Europe, manufactures pharmaceuticals.0.000000.000000.000000.00000YBritish Pound04 Aug 08Mon, 04 Aug 2008 00:00:00 ESTDate Announced: 08/04/2008Date Effective:Acq. of AssetsFriendly0.000000.000000.000000.000000.000000.00000Price/Share0.00000199.878 British Pound199.878000.00000199.878 British Pound199.878000.000000.000000.000000.00000199.87800199.878 British Pound1.96100N199.878000.000000.000000.000000.000000.00000392.00100392.001000.000000.000000.000000.000000.000000.000000.00000100.000000.000000.000000.000000.000002.331000.000000.000002.331003237.535000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.00000UK - Meda AB agreed to acquirethe European operations ofValeant PharmaceuticalsInternational, an AlisoViejo-based manufacturer ofpharmaceuticals, for 199.878mil British pounds (2.379 bilSwedish kronor/$392 mil US) incash. The transaction wassubject to regulatoryapproval. The transaction wasto exclude operations inPoland, Hungary, Slovakia, andthe Czech Republic.UK - Meda AB agreed to acquire the European operations of Valeant Pharmaceuticals International, an Aliso Viejo-based manufacturer of pharmaceuticals, for 199.878 mil British pounds (2.379 bil Swedish kronor/$392 mil US) in cash. The transaction was subject to regulatory approval. The transaction was to exclude operations in Poland, Hungary, Slovakia, and the Czech Republic.UK - Meda AB agreed to acquire the European operations of Valeant PharmaceuticalsInternational, an Aliso Viejo-based manufacturer of pharmaceuticals, for 199.878 milBritish pounds (2.379 bil Swedish kronor/$392 mil US) in cash. The transaction was subjectto regulatory approval. The transaction was to exclude operations in Poland, Hungary,Slovakia, and the Czech Republic.UK - Meda AB agreed to acquire the European operations of Valeant Pharmaceuticals International, an Aliso Viejo-based manufacturer of pharmaceuticals, for 199.878 mil British pounds (2.379 bil Swedishkronor/$392 mil US) in cash. The transaction was subject to regulatory approval. The transaction was to exclude operations in Poland, Hungary, Slovakia, and the Czech Republic.UK - Meda AB agreed to acquire the European operations of Valeant Pharmaceuticals International, an Aliso Viejo-based manufacturer ofpharmaceuticals, for 199.878 mil British pounds (2.379 bil Swedish kronor/$392 mil US) in cash. The transaction was subject to regulatoryapproval. The transaction was to exclude operations in Poland, Hungary, Slovakia, and the Czech Republic.Pending9205.00000952.600008926.9000027924.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.0000085.755000.000000.000000.000000.0000085.755000.000000.000000.000000.000000.000000.00000Status:PendingSTG-999.00000np0.00000-999.00000np0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000002833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances187873003StockholmSweden2834ForeignPublicMEDA A2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances2979003New YorkUnited States2834CaliforniaPublicVRX392.00100199.87800392.00100199.87800Deal InformationTF Mergers & Acquisitionshttp://www.alacrastore.com/storecontent/bir/492452bir/492452normMeda ABSwedenWholesale: Meda is a Nordic marketing organization covering Sweden, Denmark, Norway and Finland in the product areas of pharmaceuticals, medical devices and nutrition51224242109FKMEDA A6/19/2008 6:33:00 AM492452Company Profiles & FinancialsGale Company Profiles